ArticleTheranostics2018
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI.Theranostics · 2020Trial
- Experimental study of [EJNMMI research · 2026Article
- Exosomal integrin αvβ3 derived from colorectal cancer promotes the liver pre-metastatic niche formation by inducing cancer-associated fibroblasts activation.Clinical and experimental medicine · 2026Article
- The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics.Frontiers in oncology · 2026Review
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- Bispecific Radioligands (BRLs): Two Is Better Than One.Journal of clinical medicine · 2025Review
- GLUT1 as a generic biomarker enables near-infrared fluorescence molecular imaging guided precise intraoperative tumor detection in breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Phase I study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Comparative study of [Theranostics · 2025Article
- Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine-Glycine-Aspartate) Strategies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Diagnosis of Prostate Cancer with a Neurotensin-Bombesin Radioligand Combination-First Preclinical Results.Pharmaceutics · 2024Article
- A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging.European journal of nuclear medicine and molecular imaging · 2024Article
- Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.Cancer medicine · 2024Review
- Preclinical evaluation of a dual-receptor targeted tracer [European journal of nuclear medicine and molecular imaging · 2023Article
- Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?Acta pharmaceutica Sinica. B · 2023Review
- Synthesis, Radiolabeling, andACS omega · 2023Article
- Dual targeting PET tracer [Theranostics · 2023Article
- Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αPharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Jingjing ZhangDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Feng MaoDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Gang NiuLaboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland, 20892, USA.
Li PengDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Lixin LangLaboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland, 20892, USA.
Fang LiDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Hongyan YingDepartment of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Huanwen WuDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Boju PanDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhaohui ZhuDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Xiaoyuan ChenLaboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland, 20892, USA.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNNational Institute of Biomedical Imaging and Bioengineering · USPeking Union Medical College Hospital · CN
Funding
Laboratory of Molecular Imaging and NanomedicineZIAEB000073 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI CHEN, XIAOYUAN · 2010 to 2020
$32.8MMolecular Tracer and Imaging Core FacilityZICEB000087 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI LANG, LIXIN · 2017 to 2025
$11.3MAbstract
PubMed holds no abstract for this paper.
Indexed as
AdultBombesinBreast NeoplasmsFemaleGallium RadioisotopesHumansIntegrin alphaVbeta3Middle AgedOligopeptidesPositron Emission Tomography Computed TomographyReceptors, BombesinYoung Adultarginyl-glycyl-aspartic acidBombesinGallium-68Gallium RadioisotopesIntegrin alphaVbeta3OligopeptidesReceptors, BombesinBBN-RGDbreast cancerGRPRintegrin αvβ3PET
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.